We are live on
!
Find out more
FO
FT Options Portfolio holdings
AUM
$66.4M
1-Year Est. Return
18.48%
This Fund
S&P 500
This Quarter
Est. Return
+8.72%
1 Year Est. Return
+18.48%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$58.1M
AUM Growth
-$17.9M
(-24%)
Cap. Flow
-$4.42M
Cap. Flow
% of AUM
-7.61%
Top 10 Holdings %
Top 10 Hldgs %
43.93%
Holding
340
New
63
Increased
59
Reduced
56
Closed
151
Top Buys
| 1 |
CLVS
Clovis Oncology, Inc.
CLVS
|
+$2.31M |
| 2 |
Amgen
AMGN
|
+$1.97M |
| 3 |
iShares Biotechnology ETF
IBB
|
+$1.79M |
| 4 |
TSRO
TESARO, Inc.
TSRO
|
+$1.56M |
| 5 |
Clorox
CLX
|
+$1.3M |
Top Sells
| 1 |
Abbott
ABT
|
+$5.02M |
| 2 |
Akebia Therapeutics
AKBA
|
+$3.63M |
| 3 |
FL
Foot Locker
FL
|
+$2.12M |
| 4 |
General Mills
GIS
|
+$2.03M |
| 5 |
lululemon athletica
LULU
|
+$1.38M |
Sector Composition
| 1 | Healthcare | 37.51% |
| 2 | Consumer Staples | 17.11% |
| 3 | Consumer Discretionary | 2.69% |
| 4 | Communication Services | 1.36% |
| 5 | Materials | 1.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CLVS
1
DELISTED
Clovis Oncology, Inc.
CLVS
| $3.89M | 6.69% |
41,500
+37,679
| +986% | +$2.31M |
|
|
CLVS
2
CALL
DELISTED
Clovis Oncology, Inc.
CLVS
| $3.56M | 6.14% |
145,200
+131,700
| +976% | +$8.06M |
|
|
GWPH
3
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $3.36M | 5.79% |
33,557
+7,728
| +30% | +$832K |
|
|
4
General Mills
GIS
$20.3B
| $2.82M | 4.86% |
50,896
-35,501
| -41% | -$2.03M |
|
|
5
Abbott
ABT
$175B
| $2.43M | 4.19% |
50,070
-110,900
| -69% | -$5.02M |
|
|
PTLA
6
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $2.31M | 3.98% |
41,187
+31,882
| +343% | +$1.28M |
|
|
7
iShares Biotechnology ETF
IBB
$9.23B
| $2.09M | 3.6% |
20,241
+18,126
| +857% | +$1.79M |
|
|
8
Amgen
AMGN
$198B
| $2.08M | 3.58% |
+12,082
| New | +$1.97M |
|
|
TSRO
9
DELISTED
TESARO, Inc.
TSRO
| $1.51M | 2.6% |
+10,805
| New | +$1.56M |
|
10
Mondelez International
MDLZ
$78.3B
| $1.44M | 2.48% |
33,354
-7,550
| -18% | -$340K |
|
11
Alibaba
BABA
$276B
| $1.4M | 2.4% |
9,900
+45
| +0.5% | +$5.56K |
|
|
12
Clorox
CLX
$11.6B
| $1.28M | 2.21% |
+9,623
| New | +$1.3M |
|
|
GWPH
13
PUT
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $1.26M | 2.17% |
53,600
-3,000
| -5% | -$323K |
|
|
K
14
DELISTED
Kellanova
K
| $1.25M | 2.15% |
19,147
-18,154
| -49% | -$1.22M |
|
|
OTIC
15
DELISTED
Otonomy, Inc.
OTIC
| $1.1M | 1.9% |
58,407
-25,340
| -30% | -$353K |
|
16
CALL
Vertex Pharmaceuticals
VRTX
$123B
| $1.02M | 1.76% |
59,000
+42,000
| +247% | +$5.06M |
|
17
Colgate-Palmolive
CL
$74.4B
| $1.02M | 1.75% |
+13,747
| New | +$1.02M |
|
|
TSRO
18
PUT
DELISTED
TESARO, Inc.
TSRO
| $979K | 1.69% |
35,000
+12,300
| +54% | +$1.78M |
|
19
DaVita
DVA
$15.2B
| $948K | 1.63% |
14,639
+12,939
| +761% | +$857K |
|
20
AB InBev
BUD
$156B
| $796K | 1.37% |
7,209
+671
| +10% | +$76.8K |
|
|
SAGE
21
DELISTED
Sage Therapeutics
SAGE
| $783K | 1.35% |
9,830
-9,383
| -49% | -$678K |
|
|
POT
22
DELISTED
Potash Corp Of Saskatchewan
POT
| $653K | 1.12% |
40,080
-60,000
| -60% | -$993K |
|
|
CELG
23
DELISTED
Celgene Corp
CELG
| $649K | 1.12% |
+5,000
| New | +$613K |
|
|
MDCO
24
DELISTED
Medicines Co
MDCO
| $644K | 1.11% |
16,931
-7,168
| -30% | -$319K |
|
|
25
CALL
Akebia Therapeutics
AKBA
$359M
| $633K | 1.09% |
151,300
+97,600
| +182% | +$1.24M |
|
Similar funds
MC
FIM
TLIC
MKCM
ACM
MFM
VE
GFWEV
FT Options's Q2 2017 Portfolio in Review
As of Q2 2017, FT Options held 340 positions worth $58.1M, down 24% from $76M the previous quarter. Its ten largest holdings account for 44% of the portfolio.
FT Options withdrew a net $4.42M in Q2 2017, closing 151 positions and reducing 56 holdings. Its most notable exit was Foot Locker, an estimated $2.12M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 38% of assets, up from 35% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.
Against the trend, FT Options opened a new position in Amgen worth $2.08M.
- FT Options's largest Q2 2017 buy was Amgen: 12,082 shares worth $2.08M.
- FT Options added most to Clovis Oncology, Inc. in Q2 2017, an estimated $2.31M increase.
- FT Options's biggest Q2 2017 reduction was Abbott, cutting an estimated $5.02M.
- FT Options fully exited Foot Locker in Q2 2017, selling an estimated $2.12M.
- FT Options's ten largest holdings make up 44% of its $58.1M portfolio in Q2 2017.
- FT Options opened 63 new positions and closed 151 in Q2 2017.
- FT Options's portfolio value fell 24% quarter-over-quarter to $58.1M.
Based on FT Options's 13F filing for Q2 2017, filed 11 Aug 2017.